Clinical research has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs. A new study has found that ethnicity plays a significant role in non-small cell lung cancer (NSCLC) genetics and more personalized treatments may be beneficial to cancer patients.